
Carla Calagua

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11744468/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci. JCI Insight, 2022, 7, .	5.0	6
2	Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer. Cancer Research, 2022, 82, 1518-1533.	0.9	15
3	EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nature Cancer, 2021, 2, 444-456.	13.2	118
4	Phosphorylation of the androgen receptor at Ser81 is coâ€sustained by CDK1 and CDK9 and leads to ARâ€mediated transactivation in prostate cancer. Molecular Oncology, 2021, 15, 1901-1920.	4.6	19
5	A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. Clinical Cancer Research, 2021, 27, 4836-4847.	7.0	20
6	Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors. JCO Precision Oncology, 2021, 5, 1514-1522.	3.0	6
7	Primary adenocarcinoma of the bladder lacks mismatch repair deficiency and demonstrates PD-L1 expression in tumor-infiltrating immune cells, with implications in both diagnosis and therapeutics. Human Pathology, 2019, 94, 58-63.	2.0	6
8	Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. Journal of Clinical Oncology, 2019, 37, 923-931.	1.6	78
9	A phase II study of nivolumab in patients with high-risk biochemically recurrent (BCR) prostate cancer (PCa) Journal of Clinical Oncology, 2019, 37, TPS341-TPS341.	1.6	1
10	Downregulation of <i>Dipeptidyl Peptidase 4</i> Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Research, 2018, 78, 6354-6362.	0.9	42
11	Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer. Cancer Letters, 2018, 438, 97-104.	7.2	19
12	Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Research, 2018, 78, 4716-4730.	0.9	56
13	Prostate cancer susceptibility gene <i>HIST1H1A</i> is a modulator of androgen receptor signaling and epithelial to mesenchymal transition. Oncotarget, 2018, 9, 28532-28546.	1.8	7
14	Expression of PD-L1 in Hormone-naÃ ⁻ ve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. Clinical Cancer Research, 2017, 23, 6812-6822.	7.0	77